The Walter and Eliza Hall Institute of Medical Research, Melbourne, Vic., Australia.
Department of Medical Biology, University of Melbourne, Melbourne, Vic., Australia.
EMBO J. 2020 Dec 15;39(24):e105561. doi: 10.15252/embj.2020105561. Epub 2020 Nov 25.
Studies of gene-targeted mice identified the roles of the different pro-survival BCL-2 proteins during embryogenesis. However, little is known about the role(s) of these proteins in adults in response to cytotoxic stresses, such as treatment with anti-cancer agents. We investigated the role of BCL-XL in adult mice using a strategy where prior bone marrow transplantation allowed for loss of BCL-XL exclusively in non-hematopoietic tissues to prevent anemia caused by BCL-XL deficiency in erythroid cells. Unexpectedly, the combination of total body γ-irradiation (TBI) and genetic loss of Bcl-x caused secondary anemia resulting from chronic renal failure due to apoptosis of renal tubular epithelium with secondary obstructive nephropathy. These findings identify a critical protective role of BCL-XL in the adult kidney and inform on the use of BCL-XL inhibitors in combination with DNA damage-inducing drugs for cancer therapy. Encouragingly, the combination of DNA damage-inducing anti-cancer therapy plus a BCL-XL inhibitor could be tolerated in mice, at least when applied sequentially.
研究基因靶向小鼠确定了不同的抗凋亡 BCL-2 蛋白在胚胎发生过程中的作用。然而,对于这些蛋白质在成年动物中对细胞毒性应激的作用(如抗癌药物治疗)知之甚少。我们使用骨髓移植策略研究了 BCL-XL 在成年小鼠中的作用,该策略允许 BCL-XL 仅在非造血组织中缺失,以防止由于 BCL-XL 缺乏在红细胞中引起的贫血。出乎意料的是,全身γ射线照射(TBI)和 Bcl-x 基因缺失的组合导致慢性肾衰竭引起的继发性贫血,这是由于肾小管上皮细胞凋亡继发的阻塞性肾病引起的。这些发现确定了 BCL-XL 在成年肾脏中的关键保护作用,并为将 BCL-XL 抑制剂与诱导 DNA 损伤的药物联合用于癌症治疗提供了信息。令人鼓舞的是,在小鼠中,至少在顺序应用时,诱导 DNA 损伤的抗癌治疗联合 BCL-XL 抑制剂的组合是可以耐受的。